Background. Enterobacteriaceae, P. aeruginosa and A. baumannii can cause serious infections, particularly among hospitalized patients. Each of these organism groups have a propensity to exhibit resistance to many of the drugs used to manage the infections that they cause. Therefore, careful monitoring of the resistance patterns they exhibit is warranted. In this study Tigecycline Evaluation Surveillance Trial (TEST) program data were used to evaluate the in vitro activity of several key drugs against blood and respiratory isolates from Africa and the Middle East (AFME).
Methods. A total of 1,591 isolates collected from AFME (Egypt, Morocco, Mauritius, Namibia, South Africa, Tunisia, Israel, Jordan, Lebanon, Oman, Saudi Arabia; 2011-2013) were identified and tested locally by broth microdilution according to CLSI guidelines. All data were collected centrally at IHMA for analysis.
Results. The activities of the various drugs according to specimen source and organism group are provided in the Conclusion. Based on percent susceptibility and MIC 90 's amikacin, meropenem, and tigecycline were the most active agents against Enterobacteriaceae, regardless of specimen source. For P. aeruginosa amikacin was the most active with all others having percent susceptibilities near or below 80%. None of the agents had effective activity against A. baummannii.. These variations in antimicrobial susceptibilities underscore the need for continued monitoring of resistance trends among these clinical important organism groups encountered in AFME Disclosures. M. Renteria, Pfizer: Independent Contractor, Consulting fee D. Sahm, Pfizer: Independent Contractor, Consulting fee H. Leister-Tebbe, Pfizer: Employee, Salary
